Saturday 17 October 2026 Export NPCE’s income statement to Excel — free account

NeuroPace, Inc.

In the quarter to June 2026, revenue grew 17.1%, EPS grew 30.8%, free cash flow fell 78.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

12.24 0.54 −4.23%

Follow NPCE

Alert me

Market cap: $438.7M
P/E: 0.0×
Fwd P/E: −27.1×
Dividend yield: —
F-score: 5/9
Altman Z: −2.52
Beneish M: −2.88
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.40

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 21.42%

Capital & Financial Ratios $m

Market Cap 438.66

Revenue 102.86

Net Income (19.11)

Free Cash Flow (11.61)

Net Debt 7.32

Current Ratio 4.94

Debt/Equity 4.97

P/E ratio 0.00

Fwd P/E (27.10)

P/S ratio 4.06

P/B ratio 35.13

Past 5Y EPS Growth —

This Y EPS Growth 16.28%

Next Y EPS Growth 47.35%

Next Y revenue growth 0.31%

Next 5Y EPS Growth 45.68%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.69%

10-year low 10-year high

P/B against its own 10 years 85.80%

10-year low 10-year high

EV/Sales against its own 10 years 59.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	66	53	61	52
Receivables	12	13	15	15
Inventory	11	13	17	18
Other	—	—	—	—
	93	81	94	86

	2023	2024	2025	Q'26
Payables	2	3	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	16	15	18	17

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.44%	29.99%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(18.21%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	22	23	—	—	—
’25	23	20	27	31	100
’24	18	19	21	21	80
’23	14	17	16	18	65
’22	11	10	11	13	46
’21	11	13	10	11	45
’20	10	8	13	11	41

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(4)	—	—	—
’25	(7)	(2)	(2)	1	(11)
’24	(8)	(4)	(2)	(5)	(18)
’23	(10)	(4)	(2)	(3)	(20)
’22	(11)	(11)	(7)	(8)	(37)
’21	(6)	(6)	(4)	(8)	(25)
’20	(7)	(3)	(5)	(6)	(22)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(4)	—	—	—
’25	(8)	(2)	(2)	0	(11)
’24	(8)	(4)	(2)	(5)	(18)
’23	(10)	(4)	(2)	(3)	(20)
’22	(12)	(11)	(7)	(8)	(37)
’21	(6)	(6)	(5)	(8)	(25)
’20	(7)	(3)	(5)	(6)	(22)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.18)	—	—	—
’25	(0.21)	(0.26)	(0.11)	(0.08)	(0.66)
’24	(0.32)	(0.26)	(0.19)	(0.18)	(0.93)
’23	(0.41)	(0.36)	(0.28)	(0.23)	(1.27)
’22	(0.47)	(0.52)	(0.48)	(0.45)	(1.91)
’21	(32.73)	(0.48)	(0.34)	(0.44)	(2.17)
’20	(33.32)	(43.53)	(20.43)	(21.16)	(118.43)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	8.29	1.22	1.38	5.45	7.56	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	27.38	12.06	10.32	18.15	18.98
People
People	Employees	—	—	—	—	152	166	167	171	184	209
	Revenue/emp, $m	—	—	—	0.00	0.27	0.27	0.27	0.38	0.43	0.48
Income, $m
Income, $m	Revenue	—	—	—	37	41	45	46	65	80	100
	Gross margin, %	—	—	—	71.58	73.59	74.00	71.38	73.56	73.94	77.23
	EBT	—	—	—	(30)	(24)	(36)	(47)	(33)	(27)	(21)
	EBT margin, %	—	—	—	(81.07)	(59.02)	(79.85)	(103.43)	(50.38)	(33.97)	(21.47)
	Net income	—	0	—	(30)	(24)	(36)	(47)	(33)	(27)	(21)
	Depreciation	—	—	—	3	4	1	1	0	2	2
Per share, $
Per share, $	Revenue	—	—	—	183.12	200.67	2.72	1.85	2.53	2.74	3.06
	Earnings	—	—	—	(148.44)	(118.43)	(2.17)	(1.91)	(1.27)	(0.93)	(0.66)
	Cash flow	—	—	—	(123.95)	(105.41)	(1.48)	(1.50)	(0.76)	(0.62)	(0.34)
	Capex	—	—	—	(2.30)	(0.30)	(0.02)	(0.02)	(0.01)	(0.01)	(0.01)
	Free cash flow	—	—	—	(126.25)	(105.71)	(1.50)	(1.52)	(0.77)	(0.63)	(0.35)
	Book value	—	—	—	(640.66)	(721.13)	4.43	1.41	0.80	0.28	0.58
	Shares, m	—	—	—	0	0	17	25	26	29	33
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.16	0.16	3.71	0.78	3.86	4.08	5.05
	P/B	—	—	—	0.00	0.00	2.28	1.02	12.24	40.67	26.55
	EV/Sales	—	—	—	0.69	0.69	2.33	0.32	3.77	4.21	5.07
	EV/FCF	—	—	—	(1.39)	(1.39)	(4.22)	(0.39)	(12.42)	(18.42)	(44.69)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(25)	(22)	(25)	(37)	(20)	(18)	(11)
	Capex	—	—	—	0	0	0	(1)	0	0	0
	Free cash flow	—	—	—	(25)	(22)	(25)	(37)	(20)	(18)	(11)
Balance, $m
Balance, $m	Working capital	—	—	—	(55)	45	124	87	76	66	76
	Total debt	—	—	—	44	53	50	53	57	60	59
	Net debt	—	—	—	39	15	(66)	(24)	(9)	7	(2)
	Shareholders’ equity	—	—	—	(129)	(148)	74	35	21	8	19
Returns, %
Returns, %	ROA	—	—	—	(284.17)	(63.02)	(38.08)	(38.02)	(29.72)	(26.83)	(21.44)
	ROIC	—	—	—	0.00	0.00	(191.03)	(247.99)	(152.27)	(91.62)	(60.58)
	ROE	—	—	—	21.63	17.52	97.08	(86.96)	(118.91)	(189.35)	(158.74)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DCTH Delcath Systems, Inc.	$513.9M	1,408×	— (loss-making)	+20.60% (above 0%: growing)	−12.50% (below 0%: shrinking)	−24.45% (below 0%: shrinking)	89.75%	8.22%	Compare
MASS 908 Devices Inc.	$491.5M	— (loss-making)	— (loss-making)	+23.31% (above 0%: growing)	n/m	+150.95% (above 0%: growing)	51.90%	(79.69%)	Compare
SGHT Sight Sciences, Inc.	$484.8M	— (loss-making)	— (loss-making)	+19.55% (above 0%: growing)	n/m	+26.71% (above 0%: growing)	91.39%	(16.62%)	Compare
BWAY Brainsway Ltd. Sponsored ADR	$475.8M	24.8×	— (loss-making)	+35.43% (above 0%: growing)	+40.00% (above 0%: growing)	−51.68% (below 0%: shrinking)	74.62%	13.98%	Compare
CERS Cerus Corporation	$455.5M	— (loss-making)	— (loss-making)	+5.28% (above 0%: growing)	n/m	−20.90% (below 0%: shrinking)	55.91%	(2.94%)	Compare
NPCE NeuroPace, Inc.	$438.7M	— (loss-making)	— (loss-making)	+17.05% (above 0%: growing)	n/m	−78.70% (below 0%: shrinking)	82.83%	(22.53%)
SENS Senseonics Holdings, Inc.	$435.2M	— (loss-making)	— (loss-making)	+117.82% (above 0%: growing)	n/m	−223.24% (below 0%: shrinking)	59.10%	(248.48%)	Compare
OFIX ORTHOFIX MEDICAL INC.	$390.6M	— (loss-making)	— (loss-making)	+3.85% (above 0%: growing)	n/m	−516.58% (below 0%: shrinking)	70.97%	(3.86%)	Compare
SI Shoulder Innovations, Inc.	$382.4M	— (loss-making)	— (loss-making)	+55.95% (above 0%: growing)	n/m	−52.42% (below 0%: shrinking)	78.26%	(58.43%)	Compare
Median of peers	$465.6M	—	—	+21.96%	—	−38.07%	72.80%	(10.24%)

All 149 Medical Devices stocks →

NeuroPace, Inc. (NPCE) key facts

Concern: NeuroPace, Inc. reported a net loss of $21.5 million, or a loss of $0.66 per share, for fiscal 2025.
NeuroPace, Inc. (NPCE) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NPCE traded at $12.24, a market capitalization of $438.7 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.1× sales.
Return on equity was −158.7% and debt-to-equity 4.97.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.52 (distress zone) for fiscal 2025.